Climb Bio, Inc. CLYM
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +156.25%
- 1 year
- +415.08%
- Open
- 10.29
- Prev close
- 10.33
- Mkt cap
- 588.72M
- Vol
- 708.75K
- Avg vol
- 1.41M
- EPS
- -0.82
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.02
- High
- 10.51
- Forward P/E
- -16.92
- Beta
- 0.08
- Short ratio
- 5.77
- Inst. own
- 105.23%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 13.42
- 200-d avg
- 8.11
- 1y target
- 22.86
5D chart
Signals (78)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 9:40 AM | 2 days ago |
| SMA: Bullish | Oct 30, 9:35 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 29, 3:45 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:35 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:15 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:05 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:40 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:25 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 1:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:40 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:35 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 1:20 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:35 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:30 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:50 AM | 3 days ago |
| RSI: Overbought | Oct 29, 10:00 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:45 AM | 3 days ago |
| RSI: Overbought | Oct 28, 3:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:45 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:45 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:20 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:10 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:00 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:55 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:45 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 4 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 27, 3:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:20 PM | 5 days ago |
| RSI: Overbought | Oct 27, 1:10 PM | 5 days ago |
| RSI: Overbought | Oct 27, 1:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:30 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:10 PM | 5 days ago |
| RSI: Overbought | Oct 27, 11:00 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:40 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 5 days ago |
| RSI: Oversold | Oct 26, 3:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:40 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 3:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:25 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 1:55 PM | 6 days ago |
| RSI: Oversold | Oct 26, 1:25 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:05 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:50 PM | 6 days ago |
| SMA: Bullish | Oct 26, 11:40 AM | 6 days ago |
| RSI: Oversold | Oct 26, 10:55 AM | 6 days ago |
News
-
1 week ago benzinga.com
Reported Saturday, Climb Bio Reports Initial PrisMN Phase 2 Data Showing 200 mg Budoprutug Delivered 70% Mean PLA2R Antibody Reduction, Immunologic Remission In 5 Of 13 Patients At Week 12 In pMN
Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data; additional data from the PrisMN Phase 2 study…
1 week ago globenewswire.com
Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026
Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data; additional data from the PrisMN Phase 2 study…
-
1 week ago benzinga.com
Climb Bio And Mabworks Report Phase 1 Data Supporting Quarterly CLYM116/MIL116 Dosing For IgA Nephropathy; Phase 3 Trial Expected In 2027
>90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval~70% reduction in Gd-IgA1 at 12 weeks~33-day half-lifeNAVIGATE-2 Phase 2 trial enrolling, with initial data…
1 week ago globenewswire.com
Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026
>90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval ~70% reduction in Gd-IgA1 at 12 weeks ~33-day half-life NAVIGATE-2 Phase 2 trial enrolling, with initial data…
-
1 week ago benzinga.com
Deutsche Bank Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $28
Deutsche Bank analyst David Hoang initiates coverage on Climb Bio (NASDAQ:CLYM) with a Buy rating and announces Price Target of $28.
1 week ago zacks.com
Are Medical Stocks Lagging Climb Bio, Inc. (CLYM) This Year?
Here is how Climb Bio, Inc. (CLYM) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
3 weeks ago seekingalpha.com
Climb Bio: Others Proved APRIL Works, So The Bet Is On The 12-Week Dosing Interval
Climb Bio offers investors exposure to two key immunology assets: CLYM116 for IgA nephropathy and budoprutug for broader autoimmune indications. CLYM is well-capitalized with $239.2M in cash,…
-
1 month ago benzinga.com
Climb Bio To Present New Data For Its CLYM116, Budoprutug Programs Across Three Immune-Mediated Kidney Diseases At American Society Of Nephrology Kidney Week 2026
Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that it will present new clinical data for…
1 month ago globenewswire.com
Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug
Preliminary Phase 2 data from the ongoing PrisMN study of budoprutug in primary membranous nephropathy selected for oral presentation
-
1 month ago benzinga.com
Oppenheimer Maintains Outperform on Climb Bio, Raises Price Target to $25
Oppenheimer analyst Leland Gershell maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $18 to $25.
1 month ago benzinga.com
Robinhood To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Tuesday
Analysts raised targets for NOW, HOOD, MSTR, ABNB and CLYM, while cutting APP and IONS; ratings largely remain positive.
-
1 month ago benzinga.com
HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $30
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $24 to $30.
-
1 month ago benzinga.com
B. Riley Securities Reiterates Buy on Climb Bio, Raises Price Target to $30
B. Riley Securities analyst Mayank Mamtani reiterates Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $26 to $30.
-
1 month ago benzinga.com
BTIG Maintains Buy on Climb Bio, Raises Price Target to $32
BTIG analyst Julian Harrison maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $20 to $32.
1 month ago marketbeat.com
Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug
Climb Bio NASDAQ: CLYM presented phase I data for CLYM116, an anti-APRIL “sweeper” antibody being developed for IgA nephropathy, and said the results support advancing the program into an ongoing…
-
1 month ago benzinga.com
Baird Maintains Outperform on Climb Bio, Raises Price Target to $25
Baird analyst Colleen Kusy maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $21 to $25.
1 month ago benzinga.com
Climb Bio's Kidney Disease Therapy Gets Support for Extended Dosing Schedule
Climb Bio Inc. (NASDAQ:CLYM) on Thursday released preliminary data from its ongoing Phase 1 trial assessing CLYM116, while revealing updated strategic plans for treating IgA nephropathy, a kidney…
1 month ago benzinga.com
Climb Bio’s Kidney Disease Therapy Gets Support for Extended Dosing Schedule
Climb Bio announced positive Phase 1 data for CLYM116 and outlined its strategy to advance the IgA nephropathy candidate into Phase 3.
1 month ago globenewswire.com
Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy
~29-day half-life Single 320 mg dose of CLYM116 drove near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression through 12 weeks CLYM116 generally well-tolerated, with no serious adverse…
2 months ago globenewswire.com
Climb Bio to Present at Upcoming Investor Conferences
WELLESLEY HILLS, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases,…
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $24
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $20 to $24.
-
2 months ago benzinga.com
Truist Securities Maintains Buy on Climb Bio, Raises Price Target to $25
Truist Securities analyst Danielle Brill maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $17 to $25.
-
2 months ago benzinga.com
Climb Bio Q2 EPS $(0.18) Beats $(0.21) Estimate
Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.21) by 14.29 percent. This is a 38.46 percent decrease over losses of $(0.13)…
3 months ago defenseworld.net
Climb Bio (NASDAQ:CLYM) Shares Up 10.9% Following Analyst Upgrade
Climb Bio, Inc. (NASDAQ: CLYM - Get Free Report) shot up 10.9% on Monday after Wedbush raised their price target on the stock from $17.00 to $20.00. Wedbush currently has an outperform rating on the…
3 months ago defenseworld.net
Climb Bio (NASDAQ:CLYM) Sets New 52-Week High Following Analyst Upgrade
Climb Bio, Inc. (NASDAQ: CLYM - Get Free Report)'s stock price reached a new 52-week high during trading on Tuesday after Wedbush raised their price target on the stock from $17.00 to $20.00. Wedbush…
-
3 months ago benzinga.com
Wedbush Maintains Outperform on Climb Bio, Raises Price Target to $20
Wedbush analyst Laura Chico maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $17 to $20.
3 months ago seekingalpha.com
Climb Bio: Three Key Kidney Disease Readouts In Q4 Ought To Generate Volatility
Climb Bio: Three Key Kidney Disease Readouts In Q4 Ought To Generate Volatility
-
4 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Climb Bio, Maintains $20 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Climb Bio (NASDAQ:CLYM) with a Buy and maintains $20 price target.
-
4 months ago benzinga.com
Climb Bio Launches $100M At-The-Market Common Stock Offering Via Jefferies
Up to $100,000,000Common StockWe have entered into an Open Market Sale AgreementSM, or the Sales Agreement, with Jefferies LLC, or Jefferies, dated as of June 12, 2026, relating to the sale of shares…
4 months ago benzinga.com
Why Is Climb Bio Stock Gaining Friday?
Climb Bio Inc. (NASDAQ:CLYM) on Thursday shared initial data from its ongoing Phase 1b portion of its Phase 1b/2a study of budoprutug for primary immune thrombocytopenia (ITP), an autoimmune disorder…
4 months ago benzinga.com
Why Is Climb Bio Stock Gaining Friday?
Climb Bio (CLYM) shares positive Phase 1b data for budoprutug in ITP, showing robust B-cell depletion and strong platelet responses.
-
4 months ago benzinga.com
BTIG Maintains Buy on Climb Bio, Raises Price Target to $20
BTIG analyst Julian Harrison maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $19 to $20.
-
4 months ago benzinga.com
Climb Bio Announces Initial Data From Its Ongoing Phase 1b Portion Of Its Phase 1b/2a Study Evaluating Budoprutug In Adults With Primary Immune Thrombocytopenia
Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced initial data from the ongoing Phase 1b…
4 months ago globenewswire.com
Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
Data demonstrate favorable safety and tolerability profile, robust B-cell depletion, and encouraging platelet responses in heavily pretreated patients with primary immune thrombocytopenia Enrollment…
4 months ago benzinga.com
Tango Therapeutics, American Battery Technology, Intel And Other Big Stocks Moving Higher On Monday
U.S. stocks higher, Nasdaq Composite up 1%. Tango Therapeutics (TNGX) shares up 34.1% on positive trial data. Other big gainers include ENHA, JLHL, ABAT, BTGO, GLXY, CLYM, SOC, SRAD, AIAI, ALOY, and…
-
4 months ago benzinga.com
Guggenheim Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $35
Guggenheim analyst Yatin Suneja initiates coverage on Climb Bio (NASDAQ:CLYM) with a Buy rating and announces Price Target of $35.
-
4 months ago benzinga.com
Climb Bio Plans To Share Initial PK/PD Data And Updated Safety Data From Ongoing Phase 1 Studies Of CLYM116 In Healthy Volunteers, At Next Installment Of Its R&D Spotlight Series
The Company also announced that it plans to share initial pharmacokinetic and pharmacodynamic (PK/PD) data, as well as updated safety data from the ongoing Phase 1 studies of CLYM116 in healthy…
-
4 months ago benzinga.com
Climb Bio To Present Translational Pharmacometric Modeling And Initial Phase 1 Safety Data For CLYM116, Anti-APRIL Monoclonal Antibody, At ERA Congress 2026
Company to share additional CLYM116 clinical data and plans for further development at R&D Spotlight in late summerInitiation of CLYM116 dosing in IgAN patients in Mabworks Phase 2 study expected in…
4 months ago globenewswire.com
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
Company to share additional CLYM116 clinical data and plans for further development at R&D Spotlight in late summer
5 months ago globenewswire.com
Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026
WELLESLEY HILLS, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases,…
5 months ago marketbeat.com
Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect
Climb Bio NASDAQ: CLYM outlined its clinical development strategy and upcoming data readouts during a fireside chat at H.C. Wainwright's BioConnect Conference, with management emphasizing two…
5 months ago globenewswire.com
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress
WELLESLEY HILLS, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases,…
5 months ago globenewswire.com
Climb Bio to Present at Upcoming Investor Conferences
WELLESLEY HILLS, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases,…
-
5 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $20
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $15 to $20.
-
5 months ago benzinga.com
Wedbush Maintains Outperform on Climb Bio, Raises Price Target to $17
Wedbush analyst Laura Chico maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $15 to $17.
-
5 months ago benzinga.com
Climb Bio Q1 EPS $(0.20) Beats $(0.29) Estimate
Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.29) by 31.03 percent. This is a 35.48 percent increase over losses of $(0.31)…
5 months ago globenewswire.com
Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development CLYM116 modeling and initial Phase 1 safety data to be presented at…
-
5 months ago benzinga.com
BTIG Maintains Buy on Climb Bio, Raises Price Target to $19
BTIG analyst Julian Harrison maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $8 to $19.
-
6 months ago benzinga.com
Chardan Capital Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $22
Chardan Capital analyst Geulah Livshits initiates coverage on Climb Bio (NASDAQ:CLYM) with a Buy rating and announces Price Target of $22.
-
6 months ago benzinga.com
Oppenheimer Maintains Outperform on Climb Bio, Raises Price Target to $18
Oppenheimer analyst Leland Gershell maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $10 to $18.